Skip to main navigation

About
Research & Development
Pipeline
Investors
Careers

Press Releases

Press Releases

Year

February 2, 2023

Revolution Medicines to Participate in Upcoming Investor Conferences

January 3, 2023

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

December 19, 2022

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

December 7, 2022

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

November 9, 2022

Revolution Medicines to Participate in Upcoming Investor Conferences

November 7, 2022

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

November 1, 2022

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

September 22, 2022

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

September 1, 2022

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

August 31, 2022

Revolution Medicines to Participate in Upcoming Investor Conferences

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 20 of 107

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2023 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations